Overview
PSV359 is a clinical-stage radiopharmaceutical therapy for diagnosing and treating Fibroblast Activation Protein-alpha (FAP) expressing solid tumors. Perspective’s in-house discovery team has developed an optimized peptide targeting FAP-α with potential best-in-class characteristics as demonstrated in preclinical models. PSV359 uses Perspective Therapeutics' proprietary chelator (PSC) to bind Pb-203 for SPECT imaging and Pb-212 for alpha particle therapy.
Development
- US Therapeutic Dose Finding Trial recruiting currently throughout the US -- https://clinicaltrials.gov/study/NCT06710756
- Preclinical data indicates superiority of therapeutic effect vs other FAP-targeted therapeutics
- First-in-human imaging with [203Pb]PSV359 and [68Ga]VMT02 in multiple tumor types indicates rapid uptake, tumor retention and fast clearance